Arbutus Biopharma Corporation: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Arbutus Biopharma Corporation listata cu simbolul US.ABUS ==Descriere companie== Arbutus Biopharma Corporation (http://www.arbutusbio.com/) is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to prov...) |
(Nicio diferență)
|
Versiunea de la data 18 septembrie 2024 15:34
Pagina dedicata companiei Arbutus Biopharma Corporation listata cu simbolul US.ABUS
Descriere companie
Arbutus Biopharma Corporation (http://www.arbutusbio.com/) is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.
Grafic actiuni companie